Cas:13216-34-7 3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea manufacturer & supplier

Chemical Name:3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea

CAS.NO:13216-34-7

Synonyms:3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea

Molecular Formula:C₁₀H₁₆N₂O

Molecular Weight:180.24700

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.83000

Exact Mass:180.12600

LogP:1.11640

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea Use and application,3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea technical grade,usp/ep/jp grade.

Related News: The CTSuccess service uses Catalent��s proprietary StartScoreTM evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics. 3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea manufacturer In order to find answers to these questions, our staff in the development department set about conducting a series of experiments. 3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea vendor The CTSuccess service uses Catalent��s proprietary StartScoreTM evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics. 3-(2,3,4,5,6,7-hexahydro-1H-tricyclo[2.2.1.02,6]heptan-3-yl)-1,1-dimethylurea factory Alira’s work spans the gamut from transaction advisory to regulatory services to advanced analytics, management consulting, product development and clinical investigator training, to name a few. With the CROS NT deal, Alira secures not only a biometrics presence but also a portfolio of electronic data capture systems.